Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_24867 details
Primary information
SALIDSAL_24867
Biomarker namehsa-miR-3663-3p
Biomarker TypeNA
Sampling MethodTwo phases were designed in this study, a discovery phase and a validation phase. In the discovery phase, 6 salivary samples from 3 MPE patients, and 3 healthy controls (HCs) were randomly enrolled.
Collection MethodAt least 3 mL of saliva was collected from each subject.
Analysis MethodqPCR
Collection SiteSupernatant Saliva
Disease CategoryCancer
Disease/ConditionMalignant Pleural Effusion
Disease SubtypeNA
Fold Change/ Concentration2.403
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID32953502
Year of Publication2020
Biomarker IDhsa-miR-3663-3p
Biomarker CategorymiRNA
SequenceUGAGCACCACACAGGCCGGGCGC
Title of studySalivary microRNAs show potential as biomarkers for early diagnosis of malignant pleural effusion
Abstract of studyBACKGROUND: Malignant pleural effusion (MPE) is a common medical problem caused by multiple malignancies, especially lung cancers, and always comes along with a poor outcome. Early detection and diagnosis are important for improving the prognosis in patients with MPE. Salivary microRNAs (miRNAs) may represent a relatively convenient way for diagnosing MPE. We investigated the characteristics of salivary miRNAs of MPE patients, benign pleural effusion (BPE) patients, patients with a malignant tumor but without pleural effusion (MT), and healthy controls (HCs). We believe that they may show potential as a non-invasive and convenient biomarker for diagnosing MPE.METHODS: From January 1, 2019, to July 1, 2019, 57 MPE patients, 33 BPE patients, 50 MT patients, and 49 HCs were enrolled. To select candidate biomarkers, in the discovery phase, the salivary miRNA profiles were detected in three MPE patients and three HCs. Then, qPCR was used in the validation phase with 54 MPE patients, 33 BPE patients, 50 MT patients, and 46 HCs to assay the selected miRNAs.RESULTS: hsa-miR-4484 and hsa-miR-3663-3p were identified as potential biomarkers to diagnose MPE patients, with areas under the curve (AUC) of 0.768 and 0.666, respectively. The diagnostic efficacy was higher when the combination of both miRNAs was used, with an AUC of 0.802. No correlation was found between the volume of MPE and the expression of salivary miRNAs.CONCLUSIONS: This study reports the characterization of salivary miRNAs collected from MPE patients. A combination of hsa-miR-4484 and hsa-miR-3663-3p showed potential discriminatory power for MPE detection, and it may be helpful for the early diagnosis of MPE, i.e., before the pleural effusion volume is too large.